Meeting
2019 Gastrointestinal Cancers Symposium
A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).
Authors
Do-Youn Oh
Seoul National University Hospital, Seoul, Korea, Republic of (South)
Do-Youn Oh , Wei-Peng Yong , Li-Tzong Chen , Ji-Won Kim , Alex Yuang-Chi Chang , Jin Hyun Park , Chih-Yi Hsieh , Hsuan-Jen Shih , Nicola McIntyre , Ying-Chen Chen , Wei-Ling Chang , Mark McHale , Bertil Lindmark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02992340
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 319)
DOI
10.1200/JCO.2019.37.4_suppl.319
Abstract #
319
Poster Bd #
G17
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
First Author: Aaron C. Tan
Poster
2020 ASCO Virtual Scientific Program
Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).
First Author: Milind M. Javle
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Varlitinib in combination with gemcitabine and cisplatin for treatment-naïve advanced biliary tract cancer.
First Author: Do-Youn Oh
Poster
2018 ASCO Annual Meeting
TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).
First Author: Milind M. Javle